Relx Plc $RELX Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC trimmed its holdings in Relx Plc (NYSE:RELX) by 2.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,215 shares of the technology company’s stock after selling 884 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Relx were worth $1,696,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RELX. Goldman Sachs Group Inc. boosted its stake in shares of Relx by 4.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,072,342 shares of the technology company’s stock worth $205,287,000 after buying an additional 173,976 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Relx by 8.3% in the 1st quarter. Ameriprise Financial Inc. now owns 3,041,132 shares of the technology company’s stock worth $154,129,000 after purchasing an additional 234,094 shares in the last quarter. Northern Trust Corp grew its stake in shares of Relx by 9.2% during the 1st quarter. Northern Trust Corp now owns 2,394,097 shares of the technology company’s stock worth $120,686,000 after purchasing an additional 202,509 shares during the period. Natixis Advisors LLC increased its holdings in shares of Relx by 0.5% during the 1st quarter. Natixis Advisors LLC now owns 1,208,467 shares of the technology company’s stock valued at $60,919,000 after purchasing an additional 5,875 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Relx by 103.4% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 444,360 shares of the technology company’s stock valued at $22,400,000 after purchasing an additional 225,947 shares in the last quarter. 15.02% of the stock is owned by institutional investors and hedge funds.

Relx Price Performance

NYSE:RELX opened at $45.84 on Thursday. Relx Plc has a 12 month low of $44.19 and a 12 month high of $56.33. The stock has a 50 day moving average of $47.49 and a two-hundred day moving average of $50.87. The company has a current ratio of 0.47, a quick ratio of 0.42 and a debt-to-equity ratio of 2.55. The firm has a market cap of $84.01 billion, a P/E ratio of 24.65, a price-to-earnings-growth ratio of 2.96 and a beta of 0.87.

Relx Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 8th were paid a $0.2634 dividend. This represents a yield of 170.0%. The ex-dividend date of this dividend was Friday, August 8th. Relx’s dividend payout ratio is currently 28.49%.

Wall Street Analysts Forecast Growth

RELX has been the topic of a number of recent analyst reports. Kepler Capital Markets raised shares of Relx from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 18th. Morgan Stanley reissued an “overweight” rating on shares of Relx in a research note on Thursday, September 11th. Weiss Ratings restated a “buy (b)” rating on shares of Relx in a research note on Wednesday. Barclays reiterated an “overweight” rating on shares of Relx in a research report on Tuesday. Finally, Wall Street Zen cut Relx from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company. Based on data from MarketBeat.com, Relx presently has an average rating of “Buy”.

Relx Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.